Skip links

Blog

vaccine-targeting-kras-in-pancreatic-and-colorectal-cancer-shows-promise

Vaccine targeting KRAS in pancreatic and colorectal cancer shows promise

A new vaccine shows encouraging early results as a potential off-the-shelf treatment for certain patients with pancreatic or colorectal cancer, according to a study co-led by researchers at Memorial Sloan Kettering Cancer Center (MSK). The vaccine targets tumors with mutations (or changes) in the KRAS gene, a driving
car-t-cells-show-promise-against-age-related-diseases-in-mice

CAR T cells show promise against age-related diseases in mice

Chimeric antigen receptor (CAR) T cells have transformed the treatment of blood cancers in recent years. And there have been positive signs the “living drugs” can be harnessed against other diseases, like autoimmune disorders. Credit: Memorial Sloan Kettering Cancer Center Highlights Laboratory research led by MSK and
targeting-treatment-resistance-in-chronic-lymphocytic-leukemia

Targeting treatment resistance in chronic lymphocytic leukemia

MIAMI, FLORIDA (EMBARGOED UNTIL FEB. 1, 2024, AT 2 P.M. ET) – New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help overcome treatment resistance in chronic
stand-up-to-cancer-announces-changes-to-scientific-advisory-committee

Stand Up to Cancer announces changes to scientific advisory committee

LOS ANGELES – February 1, 2024 – Stand Up To Cancer® (SU2C) today announced changes to its Scientific Advisory Committee (SAC), which oversees SU2C’s scientific research. Credit: Stand Up To Cancer LOS ANGELES – February 1, 2024 – Stand Up To Cancer® (SU2C) today announced
combining-ai-and-live-cell-assays-to-develop-drugs-for-“undruggable”-cancer-targets

Combining AI and live cell assays to develop drugs for “undruggable” cancer targets

University of Toronto biochemist and molecular geneticist professor Igor Stagljar, PhD, has partnered with clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine to test the effectiveness of Insilico’s AI-designed molecules against what are known as “undruggable” targets – or disease targets that have
Explore
Drag